SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending due to a significant earnings beat and positive guidance, fueled by strong data center and AI-related CPU demand that has triggered a massive price rally. The community is actively debating the sustainability of this momentum, with many longs celebrating a long-awaited breakout while others caution against euphoria, drawing comparisons to past market bubbles and questioning the company's long-term profitability.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares are surging in sympathy with strong earnings results from Intel, fueling renewed investor enthusiasm for the semiconductor sector as the AI infrastructure buildout continues to gain momentum. The community is actively debating the sustainability of this rapid rally, with many traders focused on the potential for a short squeeze while others express caution regarding the stock's parabolic valuation.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as investors struggle with a relentless, multi-week rally in semiconductor stocks that has left the fund significantly depressed and near historic lows. The community remains heavily divided, with many debating whether this semiconductor sector strength represents an unsustainable bubble nearing a "blow-off top" or a continuation of an AI-driven supercycle that makes betting against the trend a dangerous "falling knife" scenario.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing massive volatility driven by extreme AI chip demand, a semiconductor supply "super cycle," and intense community debate over whether the surge represents a historic bubble or a persistent, momentum-driven melt-up. While bulls are riding the parabolic trend with high-leverage positions and dismissing pullbacks, skeptics are actively shorting the symbol, citing comparisons to past market manias and unsustainable valuation levels.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors debate its massive market cap against high-growth semiconductor peers like AMD and Intel, with the community closely tracking its strategic partnerships and the broader impact of AI infrastructure demand. Discussion remains polarized, with many retail traders frustrated by the stock's recent sideways movement compared to the wider chip sector, while others argue that its dominant ecosystem position makes it a long-term anchor for the AI trade.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz is experiencing extreme volatility following a significant jury verdict awarding the company hundreds of millions in damages against a competitor, with the community actively debating whether this is the start of a massive short squeeze or a temporary pump. Investors are fixated on the potential for additional court-ordered disgorgement payments and the company's strong cash position, leading to aggressive discussion regarding the stock's future valuation and the potential for hedge funds to be caught in a massive short trap.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as investors react to volatility driven by the company's expansion into GLP-1 treatments and broader market concerns regarding potential competition from Amazon. The community remains divided, with bullish participants pointing to strong subscriber growth and platform potential as a catalyst for a short squeeze, while bears highlight valuation concerns and the impact of the competitive landscape on margins.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing intense volatility driven by speculative trading around Middle East ceasefire headlines and ongoing semiconductor sector concentration. Investors are actively debating whether the current rally is a sustainable AI-led bull cycle or a precarious bubble vulnerable to geopolitical shocks and unsustainable valuation levels.

Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics is experiencing extreme volatility and massive trading volume following the lifting of its IPO quotation resumption halt. Investors are closely monitoring the price action as the stock establishes its initial market footing, with active community debate focused on technical support levels and the potential for sharp intraday swings typical of newly listed biotech equities.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community speculates on a potential Coinbase listing and highlights its ongoing alignment with major financial infrastructure like XRP. Investors are actively debating the token's long-term utility versus its high supply, while monitoring for a breakout beyond current resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The brokerage believes Hims &amp; Hers' recent partnership with Novo Nordisk “could mark a turning point,” easing key legal concerns.</li><li>JPMorgan sees positives in steadier GLP-1 business, progress toward peptide legalization, revenue rebound in the second half, and the potential for additional branded partnerships.</li><li>Hims &amp; Hers expanded its GLP-1 offerings on its platform to include Eli Lilly drugs, including Zepbound, Mounjaro, and Foundayo.</li></ul>Shares of Hims &amp; Hers Health (HIMS) rose about 4% in pre-market trading on Friday after a bullish brokerage note highlighted the company’s recent partnership with Novo Nordisk, boosting optimism around its expanding GLP-1 weight-loss offerings amid intensifying competition in the space.<a href="https://stocktwits.com/symbol/HIMS">HIMS shares</a> closed lower for a third consecutive session on Thursday, declining more than 9% during the sell-off.<h2 class="st-heading-2">HIMS-NOVO Partnership Removes Key Legal Overhang</h2>JPMorgan initiated coverage of Hims &amp; Hers with an ‘Overweight’ rating and a price target of $35, according to The Fly. This represents a near 25% upside from the stock’s closing price on Thursday.Analyst Cory Carpenter believes Hims &amp; Hers recent partnership with Novo Nordisk “could mark a turning point,” easing key legal concerns and positioning the company as a broader platform spanning branded, generic, and compounded offerings.In March, Novo Nordisk <a href="https://stocktwits.com/news-articles/markets/equity/hims-platform-novo-wegovy-availability-stock-focus/cZ3sTJFRIkI">teamed</a> up with Hims &amp; Hers, allowing the telehealth platform to offer FDA-approved versions of Wegovy and Ozempic at more affordable self-pay prices, while discontinuing the promotion of compounded GLP-1 drugs.This came after Novo sued Hims &amp; Hers for patent infringement after HIMS launched a $49-per-month compounded version of Wegovy, claiming it used the same active ingredient as the branded drug.<h2 class="st-heading-2">Analyst Sees Compelling Path For Upside</h2>The brokerage noted that the company has built a leading direct-to-consumer healthcare platform, serving around 2.5 million subscribers across areas such as weight loss, women’s health, erectile dysfunction, hair loss, testosterone, and an expanding presence in international markets.Carpenter stated that a steadier GLP-1 business, progress toward peptide legalization, an expected revenue rebound in the second half, and the potential for additional branded partnerships together create a “compelling catalyst path” for upside.Hims &amp; Hers also <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-lilly-zepbound-mounjaro-foundayo-novo-ceo-netflix-early-days/cZBfUtmReRh">expanded</a> its GLP-1 offerings on its platform to include Eli Lilly drugs such as Zepbound, Mounjaro, and Foundayo.However, HIMS is facing intensifying competition after Amazon expanded its GLP-1 management program through its One Medical platform, while rival telehealth platform Ro introduced major price cuts to its weight-loss membership program.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘extremely bullish’ a day earlier, while message volumes remained ‘extremely high.’One user said HIMS’ chart is intact and the stock could climb to “at least” $40.<stembedurl>https://stocktwits.com/Biofocuses/message/651242376</stembedurl>Another user noted that the short float is still high.<stembedurl>https://stocktwits.com/Hognose/message/651248357</stembedurl>The stock has shed around 17% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-ogn-stock-rising-in-pre-market-today/cZBWU3fReTp">Why Is OGN Stock Rising In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS). (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock Gets Pre-Market Boost – JPMorgan Initiation Flags ‘Turning Point’ With Novo Nordisk

JPMorgan initiated coverage of Hims & Hers with an ‘Overweight’ rating and a price target of $35, according to The Fly.

After A Rough Week, HIMS May Have Found Its Catalyst – JPMorgan Sees ‘Compelling Path

Equity

Smith Salley Wealth Management Buys 1,519 Shares of Eli Lilly and Company $LLY

Smith Salley Wealth Management boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,974 shares of the company's stock after buying an additional 1,519 shares d...

Eli Lilly and Company $LLY is Journey Advisory Group LLC's 9th Largest Position

Journey Advisory Group LLC decreased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,055 shares of the company's stock af...

Eli Lilly and Company $LLY Shares Sold by Silphium Asset Management Ltd

Silphium Asset Management Ltd lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 50.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,385 shares of the company's stoc...

TD Waterhouse Canada Inc. Grows Stock Holdings in Eli Lilly and Company $LLY

TD Waterhouse Canada Inc. grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 93,626 shares of the company's stock after acquiring an additional 5,31...

<ul class="summary-bullets"><li>Regeneron will provide Otarmeni, its recently FDA-approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S.</li><li>Regeneron will lower the Medicaid prices of its products to match those in other developed nations.</li><li>REGN commits $9 billion in domestic R&amp;D and manufacturing capacity.</li></ul>Regeneron Pharmaceuticals (REGN) on Thursday became the 17th and the final biopharma firm to sign Trump’s drug pricing agreement, which is a pledge to lower the cost of current and future life-altering medications.&nbsp;The deal commits Regeneron to lower prices on its current and future medicines for Medicaid patients to match the lowest rates paid in other developed nations. As part of the pact, the company will sell its blockbuster cholesterol drug Praluent for $225 — down from roughly $537 — through the TrumpRx.gov direct-to-consumer platform."For too long, American patients and taxpayers have shouldered a disproportionate share of the cost of biotechnology innovation — effectively subsidizing lower drug prices for other high-income nations that have not been paying their fair share,” said Dr. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron.&nbsp;“Vilifying the biopharma industry has not produced lower prices for Americans, nor has it generated more innovation.”&nbsp;Regeneron is the last of the original 17 pharmaceutical companies that received letters from Trump in July 2025, urging them to lower drug prices in the U.S. to levels paid by other developed nations.&nbsp;Companies that have already signed similar agreements include AbbVie, Amgen, AstraZeneca, Eli Lilly, GSK and Sanofi.<h2 class="st-heading-2">Otarmeni Approval And Sale</h2>REGN on Thursday also announced that its gene therapy for genetic hearing loss, Otarmeni, received accelerated approval from the U.S. Food and Drug Administration (FDA), and the firm will be providing the treatment free of cost to Americans.&nbsp;As part of the MFN agreement, Regeneron will not be subject to future pricing mandates and will receive three years of tariff relief through an agreement with the U.S. Department of Commerce. The company also committed more than $9 billion to U.S.-based manufacturing and research-and-development infrastructure investments over the coming years.<h2 class="st-heading-2">What is Trump’s MFN</h2>The&nbsp;Most-Favored-Nation (MFN) policy is a signature healthcare initiative of the Trump administration designed to ensure that Americans do not pay more for prescription drugs than patients in other developed countries.Participating companies agree to offer deeply discounted pricing on drugs supplied to Medicaid and through the TrumpRx.gov platform.<h2 class="st-heading-2">Retail Take</h2>Retail sentiment on Stocktwits&nbsp;around REGN stock was ‘bullish’ with ‘high’ message volumes.&nbsp;One user highlighted he was bullish on REGN and UNH shares.&nbsp;<stembedurl>https://stocktwits.com/DrAzevedo/message/616338118</stembedurl> The stock lost 0.8% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

REGN Becomes Final Major Drugmaker To Sign Trump’s Drug Pricing Pledge

REGN becomes the final of the 17 drugmakers contacted by President Trump last year to sign his most favored nation (MFN) pricing agreement. 

Eli Lilly looks beyond GLP-1s with a $3 billion cancer buy

Eli Lilly announced it will acquire Kelonia Therapeutics for $3.25 billion upfront to expand its oncology and genetic medicines pipeline...

Top Medical Stocks To Keep An Eye On - April 23rd

Thermo Fisher Scientific, UnitedHealth Group, Boston Scientific, Danaher, and Eli Lilly and Company are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical...

Pharmaceutical Stocks Worth Watching - April 23rd

Eli Lilly and Company, AbbVie, and Pfizer are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded...

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT's 2026 hinges on pemvidutide, with key readouts, a phase III start, and funding strategy set to shape investor sentiment.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

Traders are buzzing about the $7B acquisition of Kelonia Therapeutics as a major strategic shift toward next-gen in vivo CAR-T cancer therapies.

Market sentiment is reacting to intensifying competition, Medicare coverage uncertainty, and expanding distribution channels like Amazon and Hims.

Investors are weighing the volatile price action and heavy accumulation ahead of the highly anticipated earnings call on April 30th.

LLY
Lilly(Eli) & Co

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LLY News

LLYLilly(Eli) & Co